<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="47671">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02485600</url>
  </required_header>
  <id_info>
    <org_study_id>P14-506</org_study_id>
    <nct_id>NCT02485600</nct_id>
  </id_info>
  <brief_title>Observational Study Evaluating Long-term Health Outcomes of Canadian DUODOPA-treated Patients</brief_title>
  <official_title>Canadian Advanced Parkinson DUODOPA-Treated Patients Observational Study Evaluating Long-Term Health Outcomes in Centers of Excellence (CADENCE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, postmarketing, observational study to document health outcomes, in
      Canadian patients with advanced Parkinson's disease and long-term treatment with Duodopa
      (levodopa/carbidopa intestinal gel).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in participant's motor symptoms</measure>
    <time_frame>Baseline, Day 1, Month 3, Month 6, and every 6 months thereafter</time_frame>
    <description>Evaluated via the Unified Parkinson's Disease Rating Scale (UPDRS) Part II, III, V and Part IV items 33-35; items 32 &amp; 39 modified as per MDS-UPDRS, and the Freezing of Gait Questionnaire (FOGQ).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the non-motor symptoms.</measure>
    <time_frame>Baseline, Day 1, Month 3, and very 6 months thereafter</time_frame>
    <description>Evaluated via the Non-Motor symptoms Scale (NMS) and the Parkinson's Disease Sleep Scale (PDSS-2).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the participant's Healthcare Resource Utilization</measure>
    <time_frame>Baseline, Month 3, and every 6 months thereafter</time_frame>
    <description>Evaluated via the Health Care Resources Utilization Questionnaire (HCRU).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the Parkinson's Disease Questionnaire (PDQ-39)</measure>
    <time_frame>Baseline, Day 1, Month 3, and every 6 months thereafter</time_frame>
    <description>Evaluated via the Parkinson's Disease Questionnaire (PDQ-39)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in caregiver work productivity</measure>
    <time_frame>Baseline, Day 1, Month 3, and every 6 months thereafter</time_frame>
    <description>Evaluated by the Work Productivity and Activity Information Questionnaire (WPAI - care giver)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in caregiver burden</measure>
    <time_frame>Baseline, Day 1 , Month 3, and every 6 months thereafter</time_frame>
    <description>Evaluated via the Zarit Care Giver Burden Questionnaire.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the cognitive functions.</measure>
    <time_frame>Baseline, Day 1, and every 12 months thereafter</time_frame>
    <description>Evaluated via the Montreal Cognitive Assessment (MoCa).</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Advanced Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>DUODOPA patients.</arm_group_label>
    <description>Patients starting DUODOPA treatment at time of enrollment.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The patient population will consist of patients eligible for DUODOPA treatment according
        to the DUODOPA Product Monograph (DPM) approved by Health Canada and according to the
        reimbursement criteria accepted by the Canadian Provincial Health Authorities or private
        insurance companies.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Diagnosed with advanced Parkinson's Disease Prescribed Duodopa by his/her treating
        physician.

        Exclusion Criteria:

        Patients who were previously treated with Duodopa. Presence of other condition that, in
        the opinion of the treating physician, prohibits the patient from participating in the
        study or obscures the assessment of the treatment of advanced PD.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Wielgosz, MS</last_name>
    <role>Study Director</role>
    <affiliation>Abbvie Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nathalie Foucault, BS</last_name>
    <phone>514-832-7702</phone>
    <email>nathalie.foucault@abbvie.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dominique Julien, MS</last_name>
    <phone>514-832-7453</phone>
    <email>dominique.julien@abbvie.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 135978</name>
      <address>
        <city>Calgary</city>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 151948</name>
      <address>
        <city>Calgary</city>
        <zip>T2N 4N1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 151948, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 135979</name>
      <address>
        <city>Edmonton</city>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 135979, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148808</name>
      <address>
        <city>Hamilton</city>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 148808, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 144942</name>
      <address>
        <city>Kingston</city>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 144942, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 144941</name>
      <address>
        <city>Levis</city>
        <zip>G6V 3Z1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 144941, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 138434</name>
      <address>
        <city>London</city>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 138434, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 135977</name>
      <address>
        <city>Montreal</city>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 138334</name>
      <address>
        <city>Montreal</city>
        <zip>H3G 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 138334, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 135981</name>
      <address>
        <city>Ottawa</city>
        <zip>K1Y 4E9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 135981, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 138435</name>
      <address>
        <city>Quebec City</city>
        <zip>G1J 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 138435, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148811</name>
      <address>
        <city>Sherbrooke</city>
        <zip>J1H5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 148811, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 135980</name>
      <address>
        <city>Toronto</city>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 135980, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 142014</name>
      <address>
        <city>Vancouver</city>
        <zip>V5Z 4E8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 142014, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 138436</name>
      <address>
        <city>Vancouver</city>
        <zip>V6T 2B5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 19, 2017</lastchanged_date>
  <firstreceived_date>June 26, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LCIG</keyword>
  <keyword>Duodopa</keyword>
  <keyword>Parkinson's disease</keyword>
  <keyword>Observational</keyword>
  <keyword>Cadence</keyword>
  <keyword>Levodopa-carbidopa intestinal gel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carbidopa, levodopa drug combination</mesh_term>
    <mesh_term>Carbidopa</mesh_term>
    <mesh_term>Levodopa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
